rss
Br J Ophthalmol 79:439-441 doi:10.1136/bjo.79.5.439
  • Research Article

Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium.

  1. J Cano-Parra,
  2. M Diaz-Llopis,
  3. M J Maldonado,
  4. E Vila and
  5. J L Menezo
  1. Department of Ophthalmology, La Fe University Hospital, Valencia, Spain.

      Abstract

      AIMS--A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted. METHODS--A total of 66 eyes of 54 patients with primary pterygium were treated with excision, with or without a single intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes) to evaluate the efficacy and toxicity of this adjunctive treatment. The mean follow up was 14.1 months (range 12-23 months). RESULTS--Of the 36 eyes that underwent simple excision, 14 (38.8%) exhibited recurrences whereas only one of 30 eyes (3.33%) treated with excision and intraoperative application of mitomycin C had recurrence (p = 0.0006). Neither serious ocular complications nor systemic toxicity were noted in the mitomycin C treated group. CONCLUSION--Intraoperative mitomycin C appears to be an effective and safe adjunctive treatment of primary pterygium.